NCT00993239 - Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

August 31, 2012

Study Completion Date

March 31, 2013

Conditions

Cancer

Interventions

DRUG

Birinapant (TL32711)

30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated

Trial Locations (3)

14263

Roswell Park Cancer Institute, Buffalo

19104

University of Pennsylvania Abramson Cancer Center, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia